A Phase I, Multicenter, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of NBL-015 in Patients With Advanced Solid Tumors.

Status: Not yet recruiting

Phase of Trial: Phase I

Latest Information Update: 25 Feb 2023

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

17 Jan 2023 According to a Leap Therapeutics media release, Leap Therapeutics has merged with the Flame Biosciences and subsequently combined companies are name as Leap Therapeutics.
31 Aug 2021 New trial record
25 Aug 2021 According to a NovaRock Biotherapeutics media release, the company has entered into an exclusive license agreement and strategic partnership with Flame Biosciences and proceeds from this collaboration will be primarily used to fund the clinical advancement of NBL-015.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com